Prognostic role of serum neutrophil gelatinase-associated lipocalin in cardiac arrest patients
A prospective observational study

Changshin Kang, MD, PhD, Yong Nam In, MD, PhD, Jung Soo Park, MD, PhD, Yeonho You, MD, PhD, Jin Hong Min, MD, PhD, Wonjoon Jeong, MD, PhD, Hong Joon Ahn, MD, PhD, Yong Chul Cho, MD, Seung Ryu, MD, PhD

Abstract
Accurate neurological prognostication is of the utmost importance to avoid futile treatments in patients treated with targeted temperature management (TTM) after out-of-hospital cardiac arrest (OHCA). This study aimed to investigate the prognostic value of serum neutrophil gelatinase-associated lipocalin (NGAL) by comparing with neuron-specific enolase (NSE), which is currently recommended by international guidelines in patients treated with TTM after OHCA.

The study included 85 comatose adult patients with OHCA who underwent TTM between May 2018 and December 2020. Serum NGAL and NSE were measured at 24-hour intervals until 72 hours after return of spontaneous circulation (ROSC). The primary outcome was their prognostic performance for poor neurological outcome at 3 months after OHCA.

Forty-nine patients (57.6%) had a poor neurological outcome; NGAL levels at all time points measured were significantly higher in these patients than in those with a good outcome (P < .01). NGAL showed lower maximal sensitivity (95% confidence interval [CI]) under a false-positive rate of 0% for the primary outcome compared with NSE (18.2% [95% CI 8.2–32.7] vs 66.7% [95% CI 50.5–80.4]). The combination of NGAL with NSE at 48 h showed the highest sensitivity (69.1% [95% CI 52.9–82.4]) and had the highest area under the curve (0.91 [95% CI 0.81–0.96]) for a poor outcome. The prognostic performance of NGAL alone was inadequate at all time points. However, NGAL combined with NSE at 24 and 28 hours after ROSC showed improved sensitivity compared to NGAL alone.

NGAL should be considered a supplementary biomarker in combination with NSE for prognostication in patients with OHCA treated with TTM.

Abbreviations: AKI = acute kidney injury, AUROC = area under the ROC curve, CA = cardiac arrest, CI = confidence interval, CPC = cerebral performance category, ESRD = end-stage renal disease, FPR = false-positive rate, IQR = interquartile range, IV = intravenous, NGAL = neutrophil gelatinase-associated lipocalin, NSE = neuron-specific enolase, OHCA = out-of-hospital cardiac arrest, OR = odds ratio, ROC = receiver-operating characteristic, ROSC = return of spontaneous circulation, SOFA = Sequential Organ Failure Assessment, TTM = targeted temperature management, WLST = withdrawal of life-sustaining treatment.

Keywords: acute kidney injury, biomarkers, neutrophil gelatinase-associated lipocalin protein, out-of-hospital cardiac arrest, prognosis, targeted temperature management

Editor: Johannes Mayr.

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

How to cite this article: Kang C, In YN, Park JS, You Y, Min JK, Jeong W, Ahn HJ, Cho YC, Ryu S. Prognostic role of serum neutrophil gelatinase-associated lipocalin in cardiac arrest patients: A prospective observational study. Medicine 2021;100:40(e27463).
1. Introduction

Despite the numerous medical studies and clinical efforts to improve the prognosis of cardiac arrest (CA) survivors with the successful return of spontaneous circulation (ROSC), achievement of a reduction in mortality rate and an acceptable neurological outcome remains challenging in this patient population. In a previously published report, only 8% of patients had good neurological outcomes after receiving post-CA care for out-of-hospital cardiac arrest (OHCA). Considering that most comatose patients with poor neurological outcomes are considered eligible for withdrawal of life-sustaining treatment (WLST), accurate neurological prognostication is of the utmost importance to avoid futile treatments in patients destined for a poor outcome and inappropriate WLST in patients who may have a chance of neurological recovery.

For these reasons, there have been many attempts to develop methods for accurate and efficient neurological prognostication in CA survivors. In particular, various biomarkers have been investigated because of their advantages over other tools, such as the ability to obtain quantitative results and their likely independence from the effects of sedative agents. Moreover, acute kidney injury (AKI) after CA is associated with higher mortality, a poor neurological outcome, and a prolonged hospital stay. Several studies have reported that neutrophil gelatinase-associated lipocalin (NGAL) can facilitate the diagnosis of AKI in critically ill adult patients. Therefore, NGAL has been suggested as a potential biomarker for predicting the mortality risk and neurological outcomes in patients with CA.

However, to the best of our knowledge, there has not been a serial comparison between NGAL and neuron-specific enolase (NSE), which is the prognostic biomarker recommended in the current international guidelines for post-CA care when measured for the entire duration of care after CA. Although Kaneko et al reported that serum NGAL has a predictive value for the neurological outcome in patients with OHCA comparable with that of serum NSE, they only measured these biomarkers on days 1 and 2. We suggest that the analysis of biomarkers measured within 24 hours of ROSC might be insufficient to predict outcomes in patients with OHCA, considering that the median time to death of these patients has been reported to be 3.5 days (interquartile range [IQR] 1.2–9.3).

Therefore, this study aimed to compare the usefulness of serum NGAL for prognostication in patients with OHCA with that of serum NSE during the entire period of targeted temperature management (TTM) after CA. Similarly, we investigated whether a combination of serum NGAL and NSE can improve the prognostic performance of NSE by comparing the neurological outcomes when each biomarker was used alone and when they were used together.

2. Materials and methods

2.1. Study design and population

This prospective observational study included comatose adult patients with OHCA who received TTM at Chungnam National University Hospital (CNUH) between May 2018 and December 2020. The study was approved by the Institutional Review Board of our institution (CNUH-2017-10-027). Informed consent was obtained from the patients’ designated decision-makers before enrollment. Patients for whom further treatment was declined by their next-of-kin and those with a known medical history of end-stage renal disease (ESRD) were excluded.

2.2. TTM protocol

Patients were managed according to a previously published TTM protocol whereby TTM is induced using ice packs, intravenous (IV) cold saline, and TTM devices, namely, Arctic Sun and Energy Transfer Pads (Bard Medical, Louisville, CO). A target temperature of 33°C is maintained for 24 hours and monitored using a bladder or esophageal probe. Upon completion of the TTM maintenance phase, patients are rewarmed at a rate of 0.25°C per hour to 37°C. Midazolam (0.05 mg/kg as an IV bolus followed by a titrated continuous IV infusion of 0.05–0.2 mg/kg/h) and cisatracurium (0.15 mg/kg as an IV bolus followed by an infusion of up to 0.3 mg/kg/h) are administered for sedation and to control shivering, respectively. All patients received standard intensive care according to our institutional intensive care unit protocol.

2.3. Data collection and clinical variables

The following information was recorded: patient age and sex, presence of a witness at the time of collapse, bystander cardiopulmonary resuscitation, first monitored cardiac rhythm, etiology of CA, no-flow and low-flow time from CA, total dose of epinephrine until ROSC, Glasgow Coma Scale score immediately after ROSC, time interval between ROSC and measurement of the initial NGAL value, and the Sequential Organ Failure Assessment (SOFA) score.

2.4. Measurement of NGAL and NSE

Serum NGAL and NSE levels were obtained from blood samples drawn by an arterial line at 24-hour intervals until 72 hours after ROSC (ie, NGALinitial, 24, 48, and 72 and NSEinitial, 24, 48, and 72). The first NGAL and NSE measurements were obtained at the time of applying an external cooling device after several procedures for TTM, including electrocardiography, echocardiography, brain imaging, or resuscitation for sustained ROSC. NGAL and NSE values were measured using a UniCel DxC 880i chemical analyzer (Beckman Coulter Inc., Brea, CA) with the NGAL Test kit (BioPorto Diagnostics, Gentofte, Denmark) and an electrochemiluminescence immunoassay with ElecsysNSE (COBAS e801; Roche Diagnostics, Rotkreuz, Switzerland). The NGAL and NSE measurements were in the ranges of 25 to 3000 ng/mL and 0.1 to 300 ng/mL, respectively.

2.5. Outcomes

The primary outcome was the neurological outcome at 3 months after OHCA. The neurological outcomes were measured using the Glasgow-Pittsburgh cerebral performance category (CPC) scale, either by face-to-face interviews or structured telephone interviews. The interviews were conducted by an emergency physician who was well-versed with our protocols and blinded to each patient’s prognosis and clinical data. Patients were classified into 5 categories based on the CPC score as follows: CPC 1 (good performance), CPC 2 (moderate disability), CPC 3 (severe disability), CPC 4 (vegetative state), and CPC 5 (brain death or death). Of these, CPC scores 3 to 5 indicated a poor neurological outcome.
2.6. Subgroup analysis
To avoid the confounding effect of death within 72 hours after ROSC, a subgroup analysis was performed to determine the association between NGAL and outcomes in patients who survived until 72 hours after ROSC.

2.7. Statistical analysis
Categorical variables are presented as the frequency and percentage and were compared using Fisher exact test. Continuous variables are presented as the mean and standard deviation or as the median and IQR depending on the normality of the data. Differences in NGAL values between the 2 groups divided based on neurological outcomes were assessed using the Student t test or the Mann–Whitney U test. Receiver-operating characteristic (ROC) curves were constructed to determine the prognostic value of NGAL in terms of the primary outcome. An ROC curve plots the sensitivity of a measure on the y axis and (1 - sensitivity) on the x axis and measures the overall accuracy of the test. The most important summary index of the ROC curve is the area under the ROC curve (AUROC). In this study, the AUROC values of the various combinations of measurements were estimated in 2 steps. First, a probability value was obtained by binary logistic regression analysis. Second, a ROC curve analysis was performed using this probability value as a test variable. The DeLong method was used to perform a pairwise comparison of the ROC curves for serum NGAL, NSE, and their combinations at each time point. The statistical analyses were performed using IBM SPSS Statistics (version 25.0; IBM Corp., Armonk, NY) and MedCalc version 15.2.2 (MedCalc Software, Mariakerke, Belgium). Results were considered statistically significant at \( P < .05 \).

3. Results

3.1. Patient characteristics
In total, 98 comatose OHCA patients were treated by TTM during the study period, 13 of whom were excluded because of a known medical history of ESRD \( (n=9) \) or missed tests \( (n=4) \); finally, 85 patients were included in the study. Forty-nine (57.6%) patients had poor neurological outcomes corresponding to a CPC score of 3 to 5 at 3 months after OHCA (Fig. 1). The basic characteristics of the enrolled patients are shown in Table 1. The group with a poor neurological outcome were significantly less likely to have had bystander cardiopulmonary resuscitation or have a cardiac etiology and shockable rhythm; rather, they had a significantly worse Glasgow Coma Scale score, significantly prolonged no-flow and low-flow times, and a significantly higher SOFA score (Table 1).

3.2. Comparison of NGAL and NSE values between groups
All the serum NGAL and NSE values obtained were significantly higher in the group with a poor neurological outcome (Table 2). A gradual decrease in NGAL was observed in both outcome groups after the peak level at baseline, whereas NSE peaked at 24 hours in the group with a good neurological outcome and at 72 hours in the group with a poor neurological outcome (Table 2).

![Figure 1](image-url)
3.3. Prognostic performance of NGAL and NSE used alone and in combination

Figure 2 shows the AUROC values for each biomarker used alone and when used in combination. The AUROC values for the primary outcome were significantly higher at all time points measured after ROSC when the 2 biomarkers were used in combination than when NGAL was used alone (P = .03, P = .04, P < .01, and P < .01, respectively; Fig. 2), whereas the difference in these values between NSE and the combination did not reach statistical significance at any time point measured after ROSC (P = .34, .38, .40, and .55, respectively; Fig. 2). The AUROC values for NGAL decreased slightly over time, whereas those for NSE gradually increased. Thus, the AUROC values for NGAL measured at 48 hours and 72 hours after ROSC were significantly lower than those for NSE (P < .01 and P < .01, respectively; Fig. 2).

Table 3 shows the cut-off concentrations under a false-positive rate (FPR) of 0% and the corresponding sensitivity values for the 2 biomarkers when used alone in addition. NGAL showed lower sensitivity than NSE for both primary outcomes at all time points (Table 3). The highest sensitivity values and confidence intervals (CIs) for the group with a poor neurological outcome were observed at 48 hours when the 2 biomarkers were used in combination (69.1% [95% CI 52.9–82.4]; Table 3). The combination of the 2 biomarkers numerically improved the sensitivity of NSE for the primary outcome at 24 hours and 48 hours after ROSC, albeit without reaching the threshold for statistical significance (Table 3).

3.4. Subgroup analysis

Seventy-three patients remained alive at the end of TTM. The subgroup analysis without missing serum NGAL data is shown in Table 4. In the group with a poor neurological outcome, the AUROC values for NGALinitial, 24, 48, and 72 were 0.70 (95% CI 0.59–0.80), 0.71 (95% CI 0.59–0.81), 0.67 (95% CI 0.55–0.78), and 0.68 (95% CI 0.56–0.78), respectively (Table 4). Their sensitivity values with an FPR of 0% were 14.6% (95% CI 5.6–29.2), 9.8% (95% CI 2.7–23.1), 12.2% (95% CI 4.1–26.2), and 12.2% (95% CI 4.1–26.2), respectively (Table 4).

Table 2: The serum concentration of neuron-specific enolase and neutrophil gelatinase-associated lipocalin.

| Value, median (IQR) | Total patients, (n = 85) | Good neurological outcome, (n = 36) | Poor neurological outcome, (n = 49) | P |
|---------------------|--------------------------|-----------------------------------|-----------------------------------|---|
| NGAL, ng/mL |
| NGALinitial (n = 85) | 163.8 (43.6–3000.0) | 108.5 (43.6–1146.0) | 256.3 (46.3–3000.0) | <.01 |
| NGAL24 (n = 85) | 149.2 (32.9–3000.0) | 95.8 (32.9–1267.0) | 238.4 (42.0–3000.0) | <.01 |
| NGAL48 (n = 79) | 129.8 (41.3–3000.0) | 90.0 (41.9–1735.2) | 186.0 (41.3–3000.0) | <.01 |
| NGAL72 (n = 73) | 111.4 (29.2–2194.8) | 79.5 (29.2–1808.3) | 126.2 (38.1–2194.8) | <.01 |
| NSE, ng/mL |
| NSEinitial (n = 85) | 31.9 (8.5–300.0) | 23.0 (8.5–54.8) | 45.7 (15.6–300.0) | <.01 |
| NSE24 (n = 85) | 39.8 (12.8–300.0) | 26.2 (12.8–85.3) | 85.2 (16.6–300.0) | <.01 |
| NSE48 (n = 79) | 35.6 (9.3–300.0) | 22.1 (9.3–64.2) | 96.7 (11.5–300.0) | <.01 |
| NSE72 (n = 73) | 40.0 (8.0–300.0) | 18.0 (8.0–144.0) | 113.4 (12.4–300.0) | <.01 |
4. Discussion

This study demonstrated not only an association of the NGAL level with the neurological outcome at 3 months in patients who had OHCA treated with TTM but also showed that NGAL has meaningful prognostic value when used in combination with NSE. The sensitivity values with an FPR of 0% and AUROC values for the primary outcome were significantly lower for NGAL used alone than those when it was used in combination with NSE at all time points and when NSE was used alone at 48 hours and 72 hours from ROSC. Notably, when combined with NSE at 24 hours and 48 hours, NGAL numerically improved the sensitivity values when compared with NSE alone.

Brain injury is the major cause of death after ROSC in patients who with a history of CA. However, a significant proportion of these patients die of non-brain injury-related causes, such as cardiovascular shock and multiple organ dysfunction, during hospitalization. Therefore, using 1 brain-specific biomarker alone is insufficient for prognostication after CA, and NGAL has been identified as a possible additional prognostic biomarker of systemic stress after CA. Present guidelines

Figure 2. Statistical analysis of the areas under the receiver-operating characteristic curve for serum NGAL and NSE used alone and in combination. The DeLong test was used for statistical comparisons between (Ⅰ) serum NSE, serum NGAL, and a combination of the two biomarkers, and (Ⅱ) serum NGAL and a combination of the two biomarkers. NGAL = neutrophil gelatinase-associated lipocalin, NSE = neuron-specific enolase.
that of either biomarker when used alone.\[23\] Our analysis using a
prognostic performance, particularly sensitivity, over and above
procalcitonin (a biomarker of extra-cerebral organ dysfunction)
controls.\[24\] Similarly, its involvement in several pathways, such
as apoptosis, bacteriostasis, renal tubule epithelial cell prolifera-
tion, and regeneration, has been reported.\[25\] NGAL has several
forms, including monomeric forms, dimers, and trimers. However,
most NGALs are monomeric (with a molecular weight of 25 kDa)
and S100 (a biomarker of cerebral damage) might improve
prognostic performance, particularly sensitivity, over and above
that of either biomarker when used alone.\[23\] Our analysis using a
combination of other biomarkers, NGAL and NSE, supports the
notion of combining cerebral and extracerebral biomarkers to
improve sensitivity. However, combining NGAL and NSE could
not significantly improve the prognostic performance of NSE
alone; hence, we suggest that this notion is exclusively valid for
extracerebral biomarkers in patients with OHCA.

To avoid the confounding effect of death within 72 hours after
ROSC, we performed a subgroup analysis of all patients who
survived until 72 hours after CA. However, the prognostic
performance of NGAL measured at all time points for both
outcomes had insensitivity of <15% with an FPR of 0%. This finding
could be explained by the causes of neurological death in
patients with CA. Witten et al reported that the rate of death after
OHCA due to the withdrawal of neurological care was higher
than that after refractory hemodynamic shock (73% vs 17%).\[13\]
This report is consistent with our

for patients receiving post-CA care recommend that prognosti-
cation should have high specificity to avoid missing the
opportunity for neurological recovery due to inappropriate
WLST because of a perceived poor neurological prognosis.\[22\] In
a previous study, Jang et al reported that a combination of
procalcitonin (a biomarker of extra-cerebral organ dysfunction)
and S100 (a biomarker of cerebral damage) might improve
prognostic performance, particularly sensitivity, over and above
that of either biomarker when used alone.\[23\] Our analysis using a
combination of other biomarkers, NGAL and NSE, supports the
notion of combining cerebral and extracerebral biomarkers to
improve sensitivity. However, combining NGAL and NSE could
not significantly improve the prognostic performance of NSE
alone; hence, we suggest that this notion is exclusively valid for
extracerebral biomarkers in patients with OHCA.

To avoid the confounding effect of death within 72 hours after
ROSC, we performed a subgroup analysis of all patients who
survived until 72 hours after CA. However, the prognostic
performance of NGAL measured at all time points for both
outcomes had insensitivity of <15% with an FPR of 0%. This finding
could be explained by the causes of neurological death in
patients with CA. Witten et al reported that the rate of death after
OHCA due to the withdrawal of neurological care was higher
than that after refractory hemodynamic shock (73% vs 17%).\[13\]
This report is consistent with our

Table 3
Prognostic performance of single and combined biomarkers.

| Biomarker alone, ng/mL | Cut-off | Sensitivity (95% CI) | Specificity (95% CI) | PPV | NPV |
|-----------------------|---------|----------------------|----------------------|-----|-----|
| NGALinitial (n=65)    | 1146.0  | 2.0 (0.1–10.0)       | 100.0 (90.3–100.0)   | 100 | 42.9 (41.9–43.8) |
| NGAL24 (n=85)         | 1267.0  | 12.2 (4.6–24.8)      | 100.0 (90.3–100.0)   | 100 | 45.6 (43.0–48.2) |
| NGAL48 (n=79)         | 1735.2  | 18.2 (8.2–32.7)      | 100.0 (90.0–100.0)   | 100 | 49.3 (45.8–52.8) |
| NGAL72 (n=74)         | 1808.3  | 5.0 (0.6–16.9)       | 100.0 (89.4–100.0)   | 100 | 46.5 (44.7–48.3) |
| NSEinitial (n=85)     | 54.8    | 44.9 (30.7–59.8)     | 100.0 (90.3–100.0)   | 100 | 57.1 (50.9–63.2) |
| NSE24 (n=85)          | 85.3    | 49.0 (34.4–63.7)     | 100.0 (90.3–100.0)   | 100 | 59.0 (52.3–65.5) |
| NSE48 (n=77)          | 64.2    | 66.7 (50.5–80.4)     | 100.0 (90.0–100.0)   | 100 | 71.4 (62.0–79.3) |
| NSE72 (n=74)          | 144.0   | 43.6 (27.8–60.4)     | 100.0 (89.7–100.0)   | 100 | 60.7 (54.0–67.1) |

Combinations

| NSEinitial + NGALinitial | 44.9 (30.7–59.8) | 100.0 (90.3–100.0) | 100 | 57.1 (50.9–63.2) |
| NSE24 + NGAL24           | 63.3 (48.3–76.6) | 100.0 (90.3–100.0) | 100 | 66.7 (58.1–74.3) |
| NSE48 + NGAL48           | 69.1 (52.9–82.4) | 100.0 (89.7–100.0) | 100 | 72.3 (62.5–80.4) |
| NSE72 + NGAL72           | 43.6 (27.8–60.4) | 100.0 (89.1–100.0) | 100 | 59.3 (52.5–65.7) |

CI = confidence interval. NPV = negative predict value. PPV = positive predict value. NGAL = neutrophil gelatinase-associated lipocalin measured at baseline (NGALinitial), 24 (NGAL24), 48 (NGAL48), 72 hours (NGAL72) after return of spontaneous circulation; NSE, neuron specific enolase measured at baseline (NSEinitial), 24 (NSE24), 48 (NSE48), 72 hours (NSE72) after return of spontaneous circulation.

Table 4
Subgroup analysis of prognostic performance for poor neurological outcome in patients who fully measured NGAL for entire 72hours of targeted temperature management.

| Total patients, (n=74) | AUROC (95% CI) | Cut-off | Sensitivity (95% CI) | Specificity (95% CI) | P  | TP  | FP  | TN  | FN  | PPV | NPV |
|-----------------------|----------------|---------|----------------------|----------------------|----|-----|-----|-----|-----|-----|-----|
| NGALinitial           | 0.70 (0.59–0.80) | 1146.0  | 2.4 (0.1–12.9)       | 100.0 (89.4–100.0)   | *  | 6   | 1   | 32  | 35  | 100 | 44.6 |
| NGAL24                | 0.71 (0.59–0.81) | 1267.0  | 7.3 (1.5–19.9)       | 100.0 (89.4–100.0)   | 0.90 ** | 4   | 1   | 32  | 37  | 80.0 | 46.5 |
| NGAL48                | 0.67 (0.55–0.78) | 1735.2  | 12.2 (4.1–26.2)      | 100.0 (89.1–100.0)   | 0.38 0.18 *** | 5   | 1   | 32  | 36  | 83.3 | 47.1 |
| NGAL72                | 0.68 (0.56–0.78) | 1808.3  | 4.9 (0.6–16.5)       | 100.0 (89.4–100.0)   | 0.47 0.33 0.97 | 5   | 1   | 32  | 36  | 83.3 | 45.8 |

NGAL = neutrophil gelatinase-associated lipocalin measured at baseline (NGALinitial); 24 (NGAL24), 48 (NGAL48), 72 hours (NGAL72) after return of spontaneous circulation; AUROC = the area under the receiver operating characteristic curve. CI = confidence interval. FN = false negative. FP = false positive. NPV = negative predict value. PPV = positive predict value. TN = true negative. TP = true positive.

References of DeLong test for statistical comparison between * NGAIinitial and the others, ** NGAL24 and NGAL48 or 72, *** NGAL48 and NGAL72.
measured at 72 hours was an optimal predictor of both mortality and neurological outcome. Another study found an association between the plasma NGAL level measured at 4 h after ROSC and a poor neurological outcome (adjusted odds ratio [OR], 1.004 [95% CI 1.001–1.007]). Moreover, Kaneko et al found that NGAL measured on day 2 (24 hours after ROSC) had a predictive value comparable with that of NSE measured at the same time point for predicting the neurological outcome. However, in their multivariate regression analysis, Choi et al found that NGAL measured immediately and 3 h after ROSC was not a significant risk factor for a poor neurological outcome (NGALROSC: OR 1.017 [95% CI 0.998–1.036], P = 0.084; NGAL3h: OR 0.997 [95% CI 0.992–1.001], P = 0.113). Therefore, the optimal time to obtain NGAL samples for prognostication in patients with OHCA is controversial. Recently, recovery from AKI after CA has been observed in a significant proportion of these patients and can be a strong predictor of a good outcome. Moreover, Park et al reported that the duration of AKI after CA was 1 day in their group that recovered from AKI. Given that the best improvement of sensitivity obtained using a combination of 2 biomarkers was observed at 24 hours after ROSC, we suggest that NGAL can have significant prognostic performance in terms of predicting a poor neurological outcome at 24 hours after ROSC in patients with OHCA.

This study has several limitations. First, it was conducted at a single center and included a small number of patients. Therefore, the extent to which our findings are generalizable is unknown. Thirteen patients who underwent TTM during our study period were excluded because of a known history of ESRD or missing data, which could have introduced a degree of selection bias and further limited the generalizability of our results. Moreover, it has not yet been determined whether the serum NGAL level is elevated when kidney ischemia occurs in these patients. Therefore, the study results are not necessarily applicable to patients with ESRD. Therefore, larger studies are required to reduce the bias arising from small sample numbers. Another limitation is that NGAL levels before CA were not estimated in this study. Three patients in our cohort experienced CA due to hyperkalemia and one because of severe metabolic acidosis. All three patients with hyperkalemia died in the hospital (CPC 5), and the patient with metabolic acidosis survived with a poor neurological outcome (CPC 4). These patients may have had progressive kidney damage before CA, resulting in elevated serum NGAL levels at baseline. Nevertheless, further studies are required to investigate serum NGAL levels at baseline before CA.

5. Conclusions
NGAL was associated with the neurological outcome in patients with OHCA treated using TTM. However, its prognostic performance was not significant when used as a single biomarker. Therefore, NGAL should be considered as a supplementary biomarker in combination with NSE for prognostication in patients with OHCA. Nonetheless, further studies with a larger sample size and less selection bias are required to confirm our results.

Author contributions
Conceptualization: Jung Soo Park.
Formal analysis: Yong Nam In, Wonjoon Jeong.

Funding acquisition: Jung Soo Park.
Investigation: Yong Nam In, Hong Joon Ahn.
Methodology: Changshin Kang, Yong Chul Cho.
Software: Changshin Kang.
Supervision: Yeonho You, Jin Hong Min.
Visualization: Changshin Kang, Jin Hong Min.
Writing – original draft: Changshin Kang, Jung Soo Park.
Writing – review & editing: Yong Nam In, Jung Soo Park, Seung Ryu.

References
[1] Geocadin RG, Callaway CW, Fink EL, et al. Standards for studies of neurological prognostication in comatose survivors of cardiac arrest: A scientific statement from the American Heart Association. Circulation 2019;140:e517–42.
[2] Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics 2019 Update: A report from the American Heart Association. Circulation 2019;139:e56–28.
[3] Sanjeevani S, Pruthi S, Kalra S, Gooi A, Kalra OP. Role of neutrophil gelatinase-associated lipocalin for early detection of acute kidney injury. Int J Crit Illn Inj Sci 2014;4:223–8.
[4] Choi YH, Lee DH, Lee JH. Serum neutrophil gelatinase-associated lipocalin at 3 hours after return of spontaneous circulation in patients with cardiac arrest and therapeutic hypothermia: Early predictor of acute kidney injury. BMC Nephrol 2020;21:389.
[5] Khawaja S, Jafri L, Siddiqui I, Hashmi M, Ghan I. The utility of neutrophil gelatinase-associated Lipocalin (NGAL) as a marker of acute kidney injury (AKI) in critically ill patients. Biomark Res 2019;7:4.
[6] Kaneko T, Fujita M, Oqino Y, Yamamoto T, Tsuruta R, Kasaoka S. Serum neutrophil gelatinase-associated lipocalin levels predict the neurological outcomes of out-of-hospital cardiac arrest victims. BMC Cardiovasc Disord 2017;17:11.
[7] Park SO, Ahn JY, Lee JY, et al. Plasma neutrophil gelatinase-associated lipocalin as an early predicting biomarker of acute kidney injury and clinical outcomes after recovery of spontaneous circulation in out-of-hospital cardiac arrest patients. Resuscitation 2016;101:84–90.
[8] Park YR, Oh JS, Jeong H, et al. Predicting long-term outcomes after cardiac arrest by using serum neutrophil gelatinase-associated lipocalin. Am J Emerg Med 2018;36:660–4.
[9] Panchal AR, Bartos JA, Cabañas JG, et al. Part 3: Adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2020;142(16 suppl 2):S366–468.
[10] Witten L, Gardner R, Holmberg MJ, et al. Reasons for death in patients successfully resuscitated from out-of-hospital and in-hospital cardiac arrest. Resuscitation 2019;136:93–9.
[11] You Y, Park J, Min J, et al. Relationship between time related serum albumin concentration, optic nerve sheath diameter, cerebrospinal fluid pressure, and neurological prognosis in cardiac arrest survivors. Resuscitation 2018;131:42–7.
[12] Longstreth WJT, Nichol G, Van Ottingham L, Hallstrom AP. Two simple questions to assess neurologic outcomes at 3 months after out-of-hospital cardiac arrest: experience from the public access defibrillation trial. Resuscitation 2010;81:530–3.
[13] DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837–45.
[14] LaVer S, Farrow C, Turner D, Nolan J. Mode of death after admission to intensive care unit following cardiac arrest. Intensive Care Med 2004;30:2126–8.
[15] Dragancea L, Rundgren M, Englund E, Friberg H, Cronberg T. The influence of induced hypothermia and delayed resuscitation on the mode of death after cardiac arrest. Resuscitation 2013;84:337–42.
[19] Lemiale V, Dumas F, Mongardon N, et al. Intensive care unit mortality after cardiac arrest: the relative contribution of shock and brain injury in a large cohort. Intensive Care Med 2013;39:1972–80.

[20] Annborn M, Nilsson F, Dankiewicz J, et al. The combination of biomarkers for prognostication of long-term outcome in patients treated with mild hypothermia after out-of-hospital cardiac arrest: A pilot study. Ther Hypothermia Temp Manag 2016;6:85–90.

[21] Cho YS, Lee BK, Lee DH, et al. Association of plasma neutrophil gelatinase-associated lipocalin with acute kidney injury and clinical outcome in cardiac arrest survivors depends on the time of measurement. Biomarkers 2018;23:487–94.

[22] Nolan JP, Sandroni C, Böttiger BW, et al. European Resuscitation Council and European Society of Intensive Care Medicine guidelines 2021: Post-resuscitation care. Resuscitation 2021;161:220–69.

[23] Jang JH, Park WB, Lim YS, et al. Combination of S100B and procalcitonin improves prognostic performance compared to either alone in patients with cardiac arrest: a prospective observational study. Medicine (Baltimore) 2019;98:e14496.

[24] Cowland JB, Borregaard N. Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics 1997;45:17–23.

[25] Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003;14:2534–43.

[26] Cai L, Rubin J, Han W, et al. The origin of multiple molecular forms in urine of HNL/NGAL. Clin J Am Soc Nephrol 2010;5:2229–35.

[27] Ronco C, Legrand M, Goldstein SL, et al. Neutrophil gelatinase-associated lipocalin: Ready for routine clinical use? An international perspective. Blood Purif 2014;37:271–85.

[28] Lee JH, Park I, You JS, et al. Predictive performance of plasma neutrophil gelatinase-associated lipocalin for neurologic outcomes in out-of-hospital cardiac arrest patients treated with targeted temperature management: A prospective observational study. Medicine (Baltimore) 2019;98:e16930.

[29] Park YS, Cho BH, Oh JH, et al. Recovery from acute kidney injury as a potent predictor of survival and good neurological outcome at discharge after out-of-hospital cardiac arrest. Crit Care 2019;23:256.

[30] Cha KC, Cho IS, Oh JH, et al. Recovery from acute kidney injury is an independent predictor of survival at 30 days only after out-of-hospital cardiac arrest who were treated by targeted temperature management. Signa Vitae 2021;17:1–8.